The Development of the Economic Model of the Drug Supply of the Population[Разработка Экономической Модели Лекарственного Обеспечения Населения]

The authors performed clinical and economic modeling of the introduction of outpatient drug supply of working age patients with arterial hypertension (AH) in view of adherence to treatment in the Russian Federation and made proposals that increase the efficiency of drug supply programs while containing costs. According to a systematic review of research, provided that patients medications for ?80% of days treatment period, the frequency of hospitalizations in patients with cardiovascular disease can be reduced by 1.43 times. By reducing the frequency of hospitalizations reduced the burden on the state management of patients with hypertension, including costs associated with hospitalization, medical emergencies (direct medical costs), the payment of temporary disability benefits (direct non-medical costs), as well as the loss of gross domestic product (indirect costs). Despite significant cost savings by reducing the frequency of hospital admissions - 4.5 billion rubles per year for a group of 5 million people (registered patients of working age with hypertension in the Russian Federation), the necessary amount of additional funds in the case of implementation of the program of outpatient drug supply will be from 3.3 billion rubles to 22.8 billion rubles in year depending on the price of drugs and the chosen strategy of public funding. However, in certain segments of patients (eg, pharmacotherapy of patients of working age with stage I hypertension) introducing mechanisms to cover the costs of drug therapy by the state can be cost-effective in the short term (1 year). Additional economic benefits of public investment in this amount of 91.7 million rubles up to 802.5 million rubles.